BP
ADAP

Ballentine Partners’s Adaptimmune Therapeutics ADAP Stock Holding History

Ballentine Partners’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,758
Closed -$15.9K – 891
2024
Q3 		$15.9K Buy
+16,758
New +$19K ﹤0.01% 844
2024
Q2 		– Sell
-14,489
Closed -$22.9K – 754
2024
Q1 		$22.9K Buy
+14,489
New +$17.5K ﹤0.01% 733

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ballentine Partners's ADAP Position: Q4 2024 in Review

Ballentine Partners sold out of Adaptimmune Therapeutics (ADAP) in Q4 2024, closing a stake of 16,758 shares — an estimated $15.9K sold.

Ballentine Partners first reported a position in ADAP in Q1 2024 and held it in 2 quarters. The position peaked at $22.9K in Q1 2024. 80 funds tracked by Wall St. Rank hold ADAP as of Q4 2024.

  • Ballentine Partners reported no remaining Adaptimmune Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Ballentine Partners sold 16,758 Adaptimmune Therapeutics shares in Q4 2024, an estimated $15.9K.
  • Ballentine Partners first reported a position in Adaptimmune Therapeutics in Q1 2024 and held it in 2 quarters.
  • Ballentine Partners's Adaptimmune Therapeutics position peaked at $22.9K in Q1 2024.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2024.

Based on Ballentine Partners's 13F filing for Q4 2024, filed 16 Jan 2025.